

(12) International Application Status Report

Received at International Bureau: 25 September 2018 (25.09.2018)

Information valid as of: 04 December 2018 (04.12.2018)

Report generated on: 19 April 2019 (19.04.2019)

(10) Publication number:

WO2019/002655

(43) Publication date:

03 January 2019 (03.01.2019)

(26) Publication language:

Spanish (ES)

(21) Application Number:

PCT/ES2018/070463

(22) Filing Date:

28 June 2018 (28.06.2018)

(25) Filing language:

Spanish (ES)

(31) Priority number(s):

P201730857 (ES)

(31) Priority date(s):

28 June 2017 (28.06.2017)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

C12Q 1/6886 (2018.01)

(71) Applicant(s):

FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA [ES/ES]; C/ Joaquín Rodrigo, N° 2 28222 Majadahonda (ES) (*for all designated states*)

UNIVERSIDAD AUTÓNOMA DE MADRID [ES/ES]; Ciudad Universitaria de Cantoblanco C/ Einstein, 3 28049 Madrid (ES) (*for all designated states*)

(72) Inventor(s):

PROVENCIO PULLA, Mariano; Universidad Autónoma de Madrid Ciudad Universitaria de Cantoblanco C/ Einstein, 3 28049 Madrid (ES)

CRUZ BERMÚDEZ, Alberto; Fundacion para la Investigacion Biomedica del Hospital Universitario Puerta de Hierro Majadahonda C/ Joaquín Rodrigo, N° 2 28222 Majadahonda (ES)

(74) Agent(s):

PONS ARIÑO, Ángel; Glorieta Rubén Darío, 4 28010 Madrid (ES)

(54) Title (EN): METHOD FOR DESIGNING A PERSONALISED THERAPY FOR AN INDIVIDUAL SUFFERING FROM CISPLATIN-RESISTANT LUNG CANCER

(54) Title (FR): PROCÉDÉ PERMETTANT DE METTRE AU POINT UNE THÉRAPIE PERSONNALISÉE POUR UN INDIVIDU QUI EST ATTEINT D'UN CANCER DU POUMON RÉSIDANT AU CISPLATINE

(54) Title (ES): MÉTODO PARA DISEÑAR UNA TERAPIA PERSONALIZADA A UN INDIVIDUO QUE PADECE CÁNCER DE PULMÓN RESISTENTE A CISPLATINO

(57) Abstract:

(EN): The present invention relates to an *in vitro* method for designing a personalised therapy for an individual suffering from cisplatin-resistant lung cancer, comprising determining the expression level of the PGC-1 alpha gene before and after the treatment with cisplatin, wherein if the expression level of said gene is greater after than before the treatment with cisplatin, the therapy then comprises the administration of a compound intended to reduce the OXPPOS function.

(FR): La présente invention concerne un procédé *in vitro* permettant de mettre au point une thérapie personnalisée pour un individu qui est atteint d'un cancer du poumon résistant au cisplatine, lequel procédé consiste à déterminer le niveau d'expression du gène PGC-1alfa avant et après le traitement avec du cisplatine, puis, si le niveau d'expression dudit gène est supérieur après le traitement avec du cisplatine qu'avant le traitement avec du cisplatine, à administrer un composé conçu pour réduire la fonction OXPPOS.

(ES): La presente invención se refiere a un método *in vitro* para diseñar una terapia personalizada a un individuo que padece cáncer de pulmón resistente a cisplatino que comprende determinar el nivel de expresión del gen PGC-1alfa antes y después del tratamiento con cisplatino, en donde si el nivel de expresión de dicho gen es mayor después que antes del tratamiento con cisplatino, entonces la terapia comprende la administración de un compuesto dirigido a disminuir la función OXPPOS.

International search report:

Received at International Bureau: 29 November 2018 (29.11.2018) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM